Scinai Immunotherapeutics (SCNI) Change in Accured Expenses (2018 - 2026)
Scinai Immunotherapeutics (SCNI) reported Change in Accured Expenses of $348000.0 for Q1 2026, up 510.53% on a YoY basis from $57000.0 in Q1 2025, and up 451.52% sequentially from -$99000.0 in Q2 2025.
Scinai Immunotherapeutics (SCNI) Change in Accured Expenses (2018 - 2026) Analysis & Trends
Scinai Immunotherapeutics (SCNI) has 7 years of Change in Accured Expenses data on file, last reported at $348000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 510.53% year-over-year to $348000.0; the trailing twelve-month figure through Mar 2026 stood at $255000.0 (up 232.12% YoY), and the FY2021 full-year result was $754000.0, down 35.99% from the prior year.
- Change in Accured Expenses advanced to $348000.0 in Q1 2026, from -$99000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $348000.0 in Q1 2026 to a low of -$369000.0 in Q1 2023.
- A 4-year average of -$58111.1 and a median of -$51000.0 in 2024 frame the typical range for Change in Accured Expenses.
- Across the five-year window, Change in Accured Expenses plunged 347.5% in 2025 and jumped 510.53% in 2026, its largest moves.
- Tracing SCNI's Change in Accured Expenses over 4 years: stood at -$232000.0 in 2023, then soared by 78.02% to -$51000.0 in 2024, then tumbled by 94.12% to -$99000.0 in 2025, then soared by 451.52% to $348000.0 in 2026.
- Business Quant data shows SCNI's Change in Accured Expenses at $348000.0 in Q1 2026, -$99000.0 in Q2 2025, and $57000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Scinai Immunotherapeutics | 3.74 Bn | 627.11 Mn | -1.12 Mn | 348,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 348,000.00 |
| Mar 31, 2026 | 348,000.00 |
| Jun 30, 2025 | -99,000.00 |
| Jun 30, 2025 | -99,000.00 |
| Mar 31, 2025 | 57,000.00 |
| Mar 31, 2025 | 57,000.00 |
| Sep 30, 2024 | -51,000.00 |
| Sep 30, 2024 | -51,000.00 |
| Jun 30, 2024 | 40,000.00 |
| Jun 30, 2024 | 40,000.00 |
| Mar 31, 2024 | -239,000.00 |
| Mar 31, 2024 | -239,000.00 |
| Sep 30, 2023 | -232,000.00 |
| Sep 30, 2023 | -232,000.00 |
| Jun 30, 2023 | 22,000.00 |
| Jun 30, 2023 | 22,000.00 |
| Mar 31, 2023 | -369,000.00 |
| Mar 31, 2023 | -369,000.00 |
| Dec 31, 2021 | 791,000.00 |
| Dec 31, 2021 | 791,000.00 |